Ischemic Mitral Regurgitation

  • Michael Salna
  • Jack H. BoydEmail author


Ischemic mitral valve regurgitation (IMR) is a common consequence of left ventricular remodeling due to chronic coronary artery disease. There are several options for surgical intervention in those with severe symptomatic IMR, ranging from various repair techniques to the AHA/ACC and AATS recommended chordal sparing mitral valve replacement in patients with certain ventricular features. Mitral valve repair may be considered for IMR during concomitant coronary artery bypass grafting if certain criteria are met, but has not been found to improve survival. Ongoing trials are also evaluating the utility of ventricular remodeling using stem cells, percutaneous therapies including leaflet apposition and annular restriction devices, as well as transcatheter mitral valve replacement.


Chordal sparing mitral valve replacement Chordal tethering Ischemic mitral regurgitation Left ventricular remodelling Papillary muscle displacement 


  1. 1.
    Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.CrossRefGoogle Scholar
  2. 2.
    Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation. 2005;111:295–301.CrossRefGoogle Scholar
  3. 3.
    Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation. 2001;103:1759–64.CrossRefGoogle Scholar
  5. 5.
    Grayburn PA, Carabello B, Hung J, et al. Defining “severe” secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol. 2014;64:2792–801.CrossRefGoogle Scholar
  6. 6.
    Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.CrossRefGoogle Scholar
  7. 7.
    Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.CrossRefGoogle Scholar
  8. 8.
    St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–90.CrossRefGoogle Scholar
  9. 9.
    Ypenburg C, Lancellotti P, Tops LF, et al. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol. 2007;50:2071–7.CrossRefGoogle Scholar
  10. 10.
    Kron IL, LaPar DJ, Acker MA, et al. 2016 update to The American Association for Thoracic Surgery (AATS) consensus guidelines: ischemic mitral valve regurgitation. J Thorac Cardiovasc Surg. 2017;153:e97–e114.CrossRefGoogle Scholar
  11. 11.
    Lee AP, Acker M, Kubo SH, et al. Mechanisms of recurrent functional mitral regurgitation after mitral valve repair in nonischemic dilated cardiomyopathy: importance of distal anterior leaflet tethering. Circulation. 2009;119:2606–14.CrossRefGoogle Scholar
  12. 12.
    Gelsomino S, van Garsse L, Luca F, et al. Impact of preoperative anterior leaflet tethering on the recurrence of ischemic mitral regurgitation and the lack of left ventricular reverse remodeling after restrictive annuloplasty. J Am Soc Echocardiogr. 2011;24:1365–75.CrossRefGoogle Scholar
  13. 13.
    Kron IL, Hung J, Overbey JR, et al. Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation. J Thorac Cardiovasc Surg. 2015;149:752–761.e751.CrossRefGoogle Scholar
  14. 14.
    Goldstone AB, Chiu P, Baiocchi M, et al. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med. 2017;377:1847–57.CrossRefGoogle Scholar
  15. 15.
    Mann DL, Kubo SH, Sabbah HN, et al. Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg. 2012;143:1036–42.CrossRefGoogle Scholar
  16. 16.
    Grossi EA, Patel N, Woo YJ, et al. Outcomes of the RESTOR-MV trial (randomized evaluation of a surgical treatment for off-pump repair of the mitral valve). J Am Coll Cardiol. 2010;56:1984–93.CrossRefGoogle Scholar
  17. 17.
    Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844–54.CrossRefGoogle Scholar
  18. 18.
    Nickenig G, Estevez-Loureiro R, Franzen O, et al. Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011–2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014;64:875–84.CrossRefGoogle Scholar
  19. 19.
    Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70:2315–27.CrossRefGoogle Scholar
  20. 20.
    Pighi M, Estevez-Loureiro R, Maisano F, et al. Immediate and 12-month outcomes of ischemic versus nonischemic functional mitral regurgitation in patients treated with MitraClip (from the 2011 to 2012 pilot sentinel registry of percutaneous edge-to-edge mitral valve repair of the European Society of Cardiology). Am J Cardiol. 2017;119:630–7.CrossRefGoogle Scholar
  21. 21.
    Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefGoogle Scholar
  22. 22.
    Siminiak T, Wu JC, Haude M, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. 2012;14:931–8.CrossRefGoogle Scholar
  23. 23.
    Lipiecki J, Siminiak T, Sievert H, et al. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial. Open Heart. 2016;3:e000411.CrossRefGoogle Scholar
  24. 24.
    Maisano F, Taramasso M, Nickenig G, et al. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur Heart J. 2016;37:817–25.CrossRefGoogle Scholar
  25. 25.
    Nickenig G, Schueler R, Dager A, et al. Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. J Am Coll Cardiol. 2016;67:2927–36.CrossRefGoogle Scholar
  26. 26.
    Regueiro A, Ye J, Fam N, et al. 2-Year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10:1671–8.CrossRefGoogle Scholar
  27. 27.
    Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12–21.CrossRefGoogle Scholar
  28. 28.
    Yoon SH, Whisenant BK, Bleiziffer S, et al. Transcatheter mitral valve replacement for degenerated bioprosthetic valves and failed annuloplasty rings. J Am Coll Cardiol. 2017;70:1121–31.CrossRefGoogle Scholar
  29. 29.
    Messas E, Bel A, Morichetti MC, et al. Autologous myoblast transplantation for chronic ischemic mitral regurgitation. J Am Coll Cardiol. 2006;47:2086–93.CrossRefGoogle Scholar
  30. 30.
    Quyyumi AA, Vasquez A, Kereiakes DJ, et al. PreSERVE-AMI: a randomized, double-blind, placebo-controlled clinical trial of intracoronary administration of autologous CD34+ cells in patients with left ventricular dysfunction post STEMI. Circ Res. 2017;120:324–31.CrossRefGoogle Scholar
  31. 31.
    Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428–36.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Cardiothoracic Surgery, Department of SurgeryColumbia University Medical Center/NewYork—Presbyterian HospitalNew YorkUSA
  2. 2.Department of Cardiothoracic SurgeryStanford University School of MedicineStanfordUSA

Personalised recommendations